{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059668","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.125020+00:00","generated_at":"2026-06-02T00:12:33.345404+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Viracta Therapeutics appoints Michael Faerm as CFO, base salary $480K with stock options","bullets":["Michael Faerm appointed CFO effective May 13, 2024; previously interim CFO at Harpoon Therapeutics.","Annual base salary $480,000, target bonus up to 40% of base salary.","Initial option to purchase 500,000 shares of common stock, vesting over 4 years.","Additional option for 340,000 shares if financing extends runway through FY2025 by Dec 31, 2024.","Board increased shares reserved under Inducement Plan by 1,200,000, total 3,575,000 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059668","json":"https://secwatch.observer/filing/0000950170-24-059668.json","markdown":"https://secwatch.observer/filing/0000950170-24-059668.md","text":"https://secwatch.observer/filing/0000950170-24-059668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/virx-20240511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:12:33.345404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05e07a28c7","claim":"Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..","evidence_excerpt":"Melody Burcar, the Company’s Senior Vice President of Finance, will no longer serve as the Company’s interim principal financial officer and interim principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serve"},{"label":"Role","value":"Senior Vice President of Finance"}],"fact_type":"executive_change"},{"claim_id":"f58875e06e","claim":"Michael Faerm was appointed as Chief Financial Officer at Viracta Therapeutics, Inc..","evidence_excerpt":"On May 11, 2024, the Board of Directors (\"Board\") of Viracta Therapeutics, Inc. (the \"Company\") appointed Michael Faerm to serve as the Company’s Chief Financial Officer, effective May 13, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024059668/0000950170-24-059668-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}